These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 12799626

  • 1. A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer.
    Smith RE, Tchekmedyian NS, Chan D, Meza LA, Northfelt DW, Patel R, Austin M, Colowick AB, Rossi G, Glaspy J.
    Br J Cancer; 2003 Jun 16; 88(12):1851-8. PubMed ID: 12799626
    [Abstract] [Full Text] [Related]

  • 2. Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial.
    Schwartzberg L, Burkes R, Mirtsching B, Rearden T, Silberstein P, Yee L, Inamoto A, Lillie T.
    BMC Cancer; 2010 Oct 25; 10():581. PubMed ID: 20973982
    [Abstract] [Full Text] [Related]

  • 3. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study.
    Kotasek D, Steger G, Faught W, Underhill C, Poulsen E, Colowick AB, Rossi G, Mackey J, Aranesp 980291 Study Group.
    Eur J Cancer; 2003 Sep 25; 39(14):2026-34. PubMed ID: 12957457
    [Abstract] [Full Text] [Related]

  • 4. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo).
    Locatelli F, Canaud B, Giacardy F, Martin-Malo A, Baker N, Wilson J.
    Nephrol Dial Transplant; 2003 Feb 25; 18(2):362-9. PubMed ID: 12543893
    [Abstract] [Full Text] [Related]

  • 5. Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial.
    Vansteenkiste J, Hedenus M, Gascon P, Bokemeyer C, Ludwig H, Vermorken J, Hamilton L, Bridges K, Pujol B.
    BMC Cancer; 2009 Sep 03; 9():311. PubMed ID: 19728887
    [Abstract] [Full Text] [Related]

  • 6. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study.
    Provenzano R, Bhaduri S, Singh AK, PROMPT Study Group.
    Clin Nephrol; 2005 Aug 03; 64(2):113-23. PubMed ID: 16114787
    [Abstract] [Full Text] [Related]

  • 7. Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis.
    Macdougall IC, Matcham J, Gray SJ, NESP 960245/246 Study Group.
    Nephrol Dial Transplant; 2003 Mar 03; 18(3):576-81. PubMed ID: 12584282
    [Abstract] [Full Text] [Related]

  • 8. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia.
    Boccia R, Malik IA, Raja V, Kahanic S, Liu R, Lillie T, Tomita D, Clowney B, Silberstein P.
    Oncologist; 2006 Apr 03; 11(4):409-17. PubMed ID: 16614237
    [Abstract] [Full Text] [Related]

  • 9. Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis.
    Mirtsching B, Charu V, Vadhan-Raj S, Colowick AB, Rossi G, Tomita D, McGuire WP.
    Oncology (Williston Park); 2002 Oct 03; 16(10 Suppl 11):31-6. PubMed ID: 12435171
    [Abstract] [Full Text] [Related]

  • 10. Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia.
    Hernandez E, Ganly P, Charu V, Dibenedetto J, Tomita D, Lillie T, Taylor K, ARANESP 20030232 Study Group.
    Curr Med Res Opin; 2009 Sep 03; 25(9):2109-20. PubMed ID: 19601709
    [Abstract] [Full Text] [Related]

  • 11. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
    Hertel J, Locay H, Scarlata D, Jackson L, Prathikanti R, Audhya P.
    Am J Nephrol; 2006 Sep 03; 26(2):149-56. PubMed ID: 16636531
    [Abstract] [Full Text] [Related]

  • 12. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients.
    Brunkhorst R, Bommer J, Braun J, Haag-Weber M, Gill C, Wagner J, Wagener T, German Aranesp Study Group.
    Nephrol Dial Transplant; 2004 May 03; 19(5):1224-30. PubMed ID: 14993489
    [Abstract] [Full Text] [Related]

  • 13. The efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on haemodialysis.
    Carrera F, Oliveira L, Maia P, Mendes T, Ferreira C.
    Nephrol Dial Transplant; 2006 Oct 03; 21(10):2846-50. PubMed ID: 16891642
    [Abstract] [Full Text] [Related]

  • 14. [Changing the frequency of administration of darbepoetin alfa (from weekly to fortnightly) maintains the haemoglobin levels in patients undergoing peritoneal dialysis].
    Bajo MA, Pérez Fontán M, Remón C, Sánchez-Tomero JA, Lladós F, Selgas R.
    Nefrologia; 2009 Oct 03; 29(2):136-42. PubMed ID: 19396319
    [Abstract] [Full Text] [Related]

  • 15. Every-other-week darbepoetin alfa in the correction and maintenance of haemoglobin levels in elderly patients with chronic kidney disease: post hoc subanalysis of data from two clinical trials.
    Krause MW, Raja R, Agarwal A, Silver MR, Scarlata D, Sciarra A, Kewalramani R.
    Drugs Aging; 2009 Oct 03; 26(8):665-75. PubMed ID: 19685932
    [Abstract] [Full Text] [Related]

  • 16. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis.
    Agarwal AK, Silver MR, Reed JE, Dhingra RK, Liu W, Varma N, Stehman-Breen C.
    J Intern Med; 2006 Dec 03; 260(6):577-85. PubMed ID: 17116009
    [Abstract] [Full Text] [Related]

  • 17. Darbepoetin alfa: in patients with chemotherapy-related anaemia.
    Cvetkovic RS, Goa KL.
    Drugs; 2003 Dec 03; 63(11):1067-74; discussion 1075-7. PubMed ID: 12749734
    [Abstract] [Full Text] [Related]

  • 18. Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients.
    Jadoul M, Vanrenterghem Y, Foret M, Walker R, Gray SJ.
    Nephrol Dial Transplant; 2004 Apr 03; 19(4):898-903. PubMed ID: 15031347
    [Abstract] [Full Text] [Related]

  • 19. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia.
    van Veldhuisen DJ, Dickstein K, Cohen-Solal A, Lok DJ, Wasserman SM, Baker N, Rosser D, Cleland JG, Ponikowski P.
    Eur Heart J; 2007 Sep 03; 28(18):2208-16. PubMed ID: 17681958
    [Abstract] [Full Text] [Related]

  • 20. C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis.
    Roger SD, Locatelli F, Woitas RP, Laville M, Tobe SW, Provenzano R, Golper TA, Ruangkanchanasetr P, Lee HY, Wu KD, Nowicki M, Ladanyi A, Martínez-Castelao A, Beyer U, Dougherty FC.
    Nephrol Dial Transplant; 2011 Dec 03; 26(12):3980-6. PubMed ID: 21505096
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.